PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Infant nutrition and development of type 1 diabetes

Is it possible to prevent the illness by splitting the proteins of cow's milk?

2014-06-11
(Press-News.org) Previous studies have indicated that early exposure to complex foreign proteins, such as cow's milk proteins, increases the risk of type 1 diabetes in predisposed individuals.

"Therefore, In 2002, we embarked on a large-scale study on more than 2100 infants with a family member affected by type 1 diabetes and with genetic disease susceptibility to find an answer to the question whether delaying the exposure to complex foreign proteins will decrease the risk of diabetes", tells Professor Mikael Knip from the University of Helsinki, the leader of the TRIGR Study.

After breastfeeding the babies were either weaned to a special formula, where the cow's milk proteins were split into small peptides, or to a conventional infant formula with the regular cow's milk proteins. The first study endpoint was positivity for at least two diabetes-associated autoantibodies by the age of six years.

The results show that there was no difference in the appearance of autoantibodies between the two study groups. However, the disease process resulting in clinical diabetes has clearly two phases, the first being the appearance of autoantibodies and the other the progression from autoantibody positivity to clinical disease.

"The current results do not exclude the possibility that the early dietary modification may affect the latter phase, and therefore it is extremely important to continue to follow the study participants into the final endpoint, which is the age of ten years. That endpoint will be reached in 2017", Professor Knip states.

INFORMATION: The study is published in JAMA (June 11, 2014) and mainly funded by the National Institutes of Health (NIH) and the Canadian Institutes of Health Research (CIHR).


ELSE PRESS RELEASES FROM THIS DATE:

New guidance on how and when to stop immunosuppressants in lupus patients

2014-06-11
A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that, for the majority of lupus patients who are in remission, it is possible to successfully stop immunosuppressant therapy without triggering a flare of their disease.1 Within two years, it was possible to stop the immunosuppressant in about 70% of clinically stable patients. Half were successful within three years, and this proportion remained stable for up to five years.1 Lupus is a chronic inflammatory disease that can affect any organ system, but mainly involves ...

First biomarkers found to predict severe osteoarthritis

2014-06-11
The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) identify a correlation between the presence of biomarkers in the blood, known as micro RNAs (miRNAs), and the development of severe osteoarthritis (OA) of the knee or hip joint. The findings suggest that miRNAs may be used as biomarkers to predict severe OA disease in individuals.2 Preventative measures and early treatments are considered to be the most effective way of managing OA, but to date there has been no way of identifying the disease early on.2 "These ...

New data clarify relationship between diet and disease activity

2014-06-11
Two new studies presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) have helped clarify the relationship between the dietary intake of monounsaturated fatty acids and cholesterol with disease activity in rheumatoid arthritis (RA) and osteoarthritis (OA) respectively. In the TOMORROW study, daily intake of monounsaturated fatty acids as a component of the Mediterranean diet has been shown to be an independent predictor of remission in patients with RA; monounsaturated fatty acids might therefore be suppressing disease activity1 In another ...

One-third of psoriatic arthritis patients are not receiving optimal dosing of adalimumab

2014-06-11
Data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.1 Further data revealed that, in the case of the TNFα inhibitor infliximab, nearly three-quarters of PsA patients were on doses lower than recommended in international guidelines. 2 In the first study, after 28 weeks of treatment one-third of PsA patients were ...

Romosozumab signif increases bone mineral density and bone content compared with teriparatide

2014-06-11
A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) shows that in postmenopausal women with low bone mass, romosozumab significantly increased bone mineral density and bone content in both the spine and hip compared to baseline, and also compared with the commonly prescribed anabolic agent teriparatide and placebo.1 Romosozumab, administered subcutaneously at monthly intervals over a period of 12 months, resulted in gains in both the trabecular* and cortical† compartments of the spine and hip regions, with important differences ...

Biosimilar CT-P13 matches infliximab in improving ankylosing spondylitis disease activity

2014-06-11
New data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) show that the newly-approved infliximab biosimilar CT-P13 achieves statistically similar improvements in disease activity, disability and mobility in patients with Ankylosing Spondylitis (AS) compared to its original reference product infliximab (INX).1 CT-P13 is the world's first biosimilar monoclonal antibody to receive a positive opinion from an advanced and developed nations' regulatory body. According to Dr Won Park, Inha University Hospital, Korea, and lead investigator ...

New patient empowerment and educational initiatives unveiled at EULAR 2014

2014-06-11
Five different presentations at the European League Against Rheumatism Annual Congress (EULAR 2014) have introduced new patient empowerment and educational initiatives, which are predicted to bring significant benefits to the many thousands of patients worldwide who suffer from a rheumatic disease. These initiatives include: A new model of patient care involving self-monitoring and patient initiated follow-up1 An online learning resource to prepare patients and carers to actively engage in research, guideline development, advocacy and media activities2 A new patient ...

EULAR driving research and innovation in rheumatic and RMDs in Europe

2014-06-11
The European League Against Rheumatism (EULAR) has announced today at its Annual Congress major successes in driving the public agenda for addressing the escalating burden of RMDs in Europe. These advances include: Recognition for Rheumatic and Musculoskeletal Diseases (RMDs) from major European Commission research initiative, Horizon 2020 'FOREUM', Foundation for Research in Rheumatology, grants research funding for four osteoarthritis projects in its first year. "It is with great satisfaction that we have seen a progressive dedication of EU research funds for RMDs ...

Tendon stimulation the key to repair in 'tennis elbow'

2014-06-11
New data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) show that ultrasound-guided injections of growth factors-containing platelet-rich plasma (PRP) are no more effective in treating recently developed epicondylitis than injections of saline.1 Lead researcher, Patrick Le Goux of the Hôpitaux Universitaires Paris Ile-de-France Ouest, France, commented, "while PRP injections were shown to have no inherent benefit in the treatment of epicondylitis, what is exciting is that pain scores in both treatment groups decreased significantly ...

Higher disease activity scores in obese RA patients

2014-06-11
A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that obese patients with rheumatoid arthritis (RA) have higher DAS (disease activity) scores than non-obese patients, irrespective of their disease stage.1 With clinical remission as the ultimate therapeutic goal in RA,2 several studies have demonstrated that treatment to target – a treatment approach guided by its impact on reducing DAS scores – is more effective in lowering disease activity and, ultimately, reaching remission than usual care.3-7 Because obese patients ...

LAST 30 PRESS RELEASES:

Recycled plastics can affect hormone systems and metabolism

How babies are affected by their mother’s age

‘Closed loop’ learning barriers prevent doctors from using life-saving bedside ultrasound

Simple blood test predicts cognitive decline in Alzheimer's patients, new study shows

Antimicrobial resistance genes hitch rides on imported seafood

New way to find “aged” cells marks fresh approach for research into ageing

From blood sugar to brain relief: GLP-1 therapy slashes migraine frequency

Variability in heart rate during sleep may reveal early signs of stroke, depression or cognitive dysfunction, new study shows

New method to study catalysts could lead to better batteries

Current Molecular Pharmacology impact factor rises to 2.9, achieving Q2 ranking in the Pharmacology & Pharmacy category in 2024 JCR

More time with loved ones for cancer patients spared radiation treatment

New methods speed diagnosis of rare genetic disease

Genetics of cardiomyopathy risk in cancer survivors differ by age of onset

Autism inpatient collection releases genetic, phenotypic data for more than 1,500 children with autism

Targeting fusion protein’s role in childhood leukemia produces striking results

Clear understanding of social connections propels strivers up the social ladder

New research reveals why acute and chronic pain are so different – and what might make pain last

Stable cooling fostered life, rapid warming brought death: scientists use high-resolution fusuline data reveal evolutionary responses to cooling and warming

New research casts doubt on ancient drying of northern Africa’s climate

Study identifies umbilical cord blood biomarkers of early onset sepsis in preterm newborns

AI development: seeking consistency in logical structures

Want better sleep for your tween? Start with their screens

Cancer burden in neighborhoods with greater racial diversity and environmental burden

Alzheimer disease in breast cancer survivors

New method revolutionizes beta-blocker production process

Mechanism behind life-threatening cancer drug side-effect revealed

Weighted vests might help older adults meet weight loss goals, but solution for corresponding bone loss still elusive

Scientists find new way to predict how bowel cancer drugs will stop working – paving the way for smarter treatments

Breast cancer patients’ microbiome may hold key to avoiding damaging heart side-effects of cancer therapies

Exercise-induced protein revives aging muscles and bones

[Press-News.org] Infant nutrition and development of type 1 diabetes
Is it possible to prevent the illness by splitting the proteins of cow's milk?